Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Inclusion Criteria: * Moderate to severe PsA * Inadequate response to DMARD therapy * Corticosteroid stable dose \<= 10 mg QD * DMARDs must have been taken for 3 months and stable dose for 4 weeks * MTX maximum dose = \<= 30 mg/week * Active chronic plaque PS or documented history of chronic plaque PS Exclusion Criteria: * No other active skin disease